Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases Registry
Our study confirms VRd demonstrates superior PFS compared to Rd and VCd, but was underpowered to detect a significant difference in OS. More prospective real-world studies are needed to establish the optimal choice of induction therapy balancing efficacy and toxicity for this cohort in resource limited settings.
Authors
- P. Joy Ho (ORCID: https://orcid.org/0000-0002-2811-8671)
- Rajeev Rajagopal
- Simon J Harrison
- Erica M. Wood (ORCID: https://orcid.org/0000-0001-7527-2340)
- Sarah Zhao
- Elizabeth Moore (ORCID: https://orcid.org/0000-0002-3881-6000)
- Peter N. Mollee (ORCID: https://orcid.org/0000-0002-8537-1198)
- Cameron Wellard (ORCID: https://orcid.org/0000-0002-6115-5394)
- Zoe McQuilten (ORCID: https://orcid.org/0000-0001-9698-7185)
- Hang Quach (ORCID: https://orcid.org/0000-0002-4796-3352)
- Emma-Jane McDonald
- Bradley Augustson
- Andrew Spencer
Institutions
- Royal Prince Alfred Hospital (AU)
- Middlemore Hospital (NZ)
- Peter MacCallum Cancer Centre (AU)
- Auckland City Hospital (NZ)
- Princess Alexandra Hospital (AU)
- Sir Charles Gairdner Hospital (AU)
- Christchurch Hospital (NZ)
- St Vincent's Hospital Melbourne (AU)
- Monash Health (AU)
- Alfred Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2025-08-09
- DOI
- https://doi.org/10.1016/j.clml.2025.08.004
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- Sanofi
- Gilead Sciences
- Celgene